SHENYANG XINGQI PHARMACEUTICAL CO.(SZ:300573) Guotou Securities·2025-10-29 01:41Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a target price of 98.10 CNY for the next six months [5][7]. Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, achieving 1.904 billion CNY in revenue and 599 million CNY in net profit, representing year-on-year growth of 32.27% and 105.98%, respectively [2][5]. - The overall gross margin for the company in Q1-Q3 2025 was 81.33%, an increase of 2.94 percentage points compared to the previous year, driven by the strong sales of its core product, low-concentration atropine eye drops [2][4]. - The low-concentration atropine eye drops are recognized in multiple guidelines as a foundational medication for long-term management of myopia in children and adolescents, indicating a large market potential and favorable competitive landscape [3][4]. Financial Performance - The company is expected to achieve net profits of 803 million CNY, 1.021 billion CNY, and 1.241 billion CNY for the years 2025, 2026, and 2027, reflecting year-on-year growth rates of 137.6%, 27.1%, and 21.5%, respectively [5][11]. - The projected earnings per share (EPS) for 2025 is 3.27 CNY, with a price-to-earnings (PE) ratio of 30 times [5][11]. - The company’s revenue is forecasted to grow from 2.565 billion CNY in 2025 to 3.848 billion CNY in 2027, with a compound annual growth rate (CAGR) of 20% [11][12]. Research and Development - The company is actively expanding its research and development pipeline, covering various common ophthalmic diseases, with several products making progress in clinical trials [4][5]. - Notable advancements include the initiation of phase III clinical trials for lidocaine eye gel and the completion of phase II trials for voriconazole eye drops [4].